This country spends far too much on medical bills. That’s changing.
Because Trump announced a huge change for Americans’ health you have to see.
The Program That Keeps Growing — And Keeps Working
The numbers keep getting better. And the political class that said this would never work keeps getting quieter.
President Trump announced Friday that TrumpRx.gov has added another 160 prescription drugs, bringing the total to more than 800 discounted medications — covering four out of every five prescriptions filled by American patients. The administration says the program has already saved Americans more than $400 million since its February launch. The price cuts, in some cases, reach 400%, 500%, even 600% off what Americans were previously paying for the same medications.
“TrumpRx.gov will now provide clear, transparent, and DISCOUNTED offerings for FOUR OUT OF FIVE of every prescription filled by Americans,” Trump wrote on Truth Social Friday. “These Most Favored Nations Deals have already, in fact, saved American Patients over 400 Million Dollars since the launch of TrumpRx.gov.”
The program operates through Most Favored Nation pricing arrangements finalized with 16 major pharmaceutical companies — agreements under which participating drugmakers received tariff-related exemptions in exchange for extending their lowest global prices to American cash-paying patients. Eli Lilly and Novo Nordisk are among the participants, with discounts applying to popular GLP-1 weight-loss medications. Additional discounts are now available on inhalers, HIV treatments, diabetes medications, and fertility drugs.
The Mechanism — And Why Nobody Did It Before
The structural innovation at the heart of TrumpRx is not complicated. For decades, Americans paid more for prescription drugs than consumers in other developed countries — sometimes dramatically more — because the American pharmaceutical market was structured around a thicket of middlemen who extracted margins at every stage between manufacturer and patient. Pharmacy benefit managers, insurance formularies, wholesale distributors: each layer added cost and complexity that ultimately hit the American consumer.
Most Favored Nation pricing bypasses that architecture for the covered medications. It says: whatever you charge in Germany, Japan, or Canada, charge Americans the same or less. The tariff threat provided the leverage. The agreements provided the mechanism. The website provides the transparency — patients can search for discounted medications, view estimated savings, and generate coupons without navigating an insurance bureaucracy.
Trump framed the tariff-pricing connection plainly in his Truth Social announcement: “Of course, Most Favored Nations would not be possible without my use of TARIFFS, which are getting other Countries to ‘pay up’ instead of relying on American Patients getting ripped off, as they were for decades until I ordered an immediate ‘stop’ to this very unfair and, frankly, foolish situation.”
The political objection from the pharmaceutical industry — that Most Favored Nation pricing would reduce research and development investment — is a real concern that economists have debated seriously. A forthcoming analysis from the Pence-aligned advocacy group America First Policy Institute characterized elements of the approach as “socialist.” Those critiques deserve engagement. But patients who are currently paying $300 for an inhaler that costs $40 in Canada are not in a position to be particularly moved by them.
$400 Million, And More To Come
The $400 million savings figure will be audited, challenged, and contested — that is the nature of health care economics, where the question of what a number actually measures is rarely simple. But even accepting the most conservative interpretation of the data, the program has produced real savings for real Americans in a domain — prescription drug pricing — where every previous administration of both parties produced primarily rhetoric.
Trump promised to go “BIG” on drug prices in his second term. “I was proud to make History during my First Term when we lowered Drug Prices, even if by a tiny percentage, because this amounted to a HUGE change compared to other presidents only raising Drug Prices, endlessly and significantly, every year,” he wrote Friday. “Then, during my Second Term, I decided to go BIG with Most Favored Nations Pricing.”
The program now covers most of the medications Americans use most. The administration says it will continue expanding partnerships and securing additional Most Favored Nation deals. And at a moment when the Iran war’s energy costs are the dominant economic story, TrumpRx is one of the few affordability wins the White House can point to that is both measurable and popular. The president is instructing his administration to keep going. If the trajectory holds, this one deserves to be remembered.
